---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-006817"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:31:52.384150+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Talphera Q4 net loss $4.5M; cash $9.4M; Niyad study enrollment imminent; $26M committed

## Summary
- Net loss from continuing ops of $4.5M ($0.25/sh) vs $5.9M ($1.00/sh) in Q4 2022; revenues $0.3M.
- Cash and investments $9.4M at Dec 31, 2023; senior debt fully repaid in Q2 2023.
- Jan 2024: $26M committed capital — $8M DSUVIA royalty monetization with Xoma + $18M equity from two investors.
- First patient enrollment in NEPHRO CRRT registrational study expected Q1 2024; PMA submission targeted by end 2024.
- Company rebranded from AcelRx to Talphera in Jan 2024; now trades as TLPH on Nasdaq.

## SEC filing metadata
- accession: 0001437749-24-006817
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774924006817/0001437749-24-006817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774924006817/acrx20240305_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-006817
- JSON: https://secwatch.observer/filing/0001437749-24-006817.json
- Plain text: https://secwatch.observer/filing/0001437749-24-006817.txt

## Key facts
- Earnings Releases
  TALPHERA, INC. reported the three months ended December 31, 2023 results: revenue $0.3 million, net income $4.5 million, EPS $0.25 per basic and diluted share.
  - Period: the three months ended December 31, 2023
  - Revenue: $0.3 million
  - Net income: $4.5 million
  - EPS: $0.25 per basic and diluted share
  - Result: reported results
  source text: ● The cash and cash equivalents balance was $9.4 million as of December 31, 2023. The senior debt with Oxford was fully repaid in the second quarter of 2023. ● Revenues of $0.3 million for the fourth quarter primarily represent the revenue earned on the sales of DSUVIA by Alora, principally driven by sales to the Department of Defense. Revenues in the prior
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427925/000143774924006817/0001437749-24-006817-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.